1. API PARTICLE SIZE1 2 POLYMER CONTENT FOR HARD GELATIN CAPSULE DEVELOPMENT AS PER QbD EFFECT EVALUATION OF FORMUALATION VARIABLES FOR SUSTAINED RELEASE ENCAPSULATED DOSAGE…
1. FOR EMULSION CREAM DEVELOPMENT AS PER QbD OPTIMIZATION OF OIL WATER EMULGENT RATIO IN SEMISOLID MIXTURES RISKS SEPERATION OF OILY PHASE & AQUEOUS PHASE DURING ROUTINE…
1. FOR NON-AQUEOUS PARENTERAL DEPOT DOSAGE FORM DEVELOPMENT AS PER QbD OPTIMIZATION OF CPPs OF DRY HEAT STERILIZATION PROCESS RISKS INADEQUATE EXPOSURE HIGH TEMPERATURE SAFETY…
1. FOR SOLID ORAL DOSAGE FORM DEVELOPMENT AS PER QbD OPTIMIZATION OF CRITICAL PROCESSING PARAMETERS OF DRY MIXING PROCESS RISKS INAPPROPRIATE BLENDING SPEED &/OR TIME…
1. PRODUCT TEMPERATURE4 2 SPRAY RATE ATOMIZATION PRESSURE 3 AIR VOLUME 1 SCREENING & OPTIMIZATION OF CPPs OF WURSTER COATING DRUG LAYERING PROCESS FOR MULTIUNIT PARTICULATES…
1. TESTING OF SIGNIFICANCE NO. OF FACTORS NO. OF LEVELS EXPERIMENTAL DESIGN SELECTED TOTAL NO OF EXPERIMENTAL RUNS (NO OF TRIALS) 4 2 FRACTIONAL FACTORIAL DESIGN 24-1 = 8…
1. FOR TABLET DEVELOPMENT AS PER QbD OPTIMIZATION OF CPPs OF TABLET COMPRESSION PROCESS LOWER HARDNESS INADEQUATE DISINTEGRATION QUALITY COMPROMISED EFFICACY COMPROMISED…
1. FOR SOLID ORAL DOSAGE FORM DEVELOPMENT AS PER QbD OPTIMIZATION OF CPPs OF FLUID BED TOP SPRAY GRANULATION PROCESS RISKS LOWER HARDNESS INADEQUATE DISINTEGRATION QUALITY…